Fig. 1From: Proteomic landscape subtype and clinical prognosis of patients with the cognitive impairment by Japanese encephalitis infectionOverview of proteomics landscape of CSF in patients with JE. A Workflow of the quantitative proteomic analysis for CSF samples. B Enrolment of patients with JE and collection of clinical data. C Summary of proteomics data analysis procedure for CSF of patients with JE. D Proteomic data sets filtered at different levels for various statistical analyses. D1: 411 proteins were identified in 59 samples (26 patients and 33 controls) at 1% protein level FDR; D2: high confidence unique proteins identified withāā„ā1 unique peptides with peptide FDRā<ā1% that were used for identifying differentially expressed proteins (DEPs) between JE and control; D3: 379 identified proteins with high abundance range (FOTā>ā10āāā5 in at least one case) except potential KRT contaminants; D4: 185 proteins identified in more than one-third of the samples; D5: identified 59 differentially expressed proteins with FOT ratio JE/controlā>ā3 or JE/controlā<ā1/3; D6, Separation CSF sample between JE and Con. E. PCA score plot based on all detected proteins. Patients with JE (red) were apart from the control group (blue)Back to article page